Table 2. Blood lymphocyte counts in immunocompetent human subjects before and after GC therapy in vivo.
| cell numbers (cells/ml ± SD) | frequency (% ±SD) | |||||
| cell type | before therapy | after therapy | p value | before therapy | after therapy | p value |
| leukocytes | 7.3±3.0×106 | 13.0±4.2×106 | p<0.001 | - | - | - |
| neutrophils | 4.6±2.6×106 | 9.3±3.7×106 | p<0.001 | 60.4±11.6# | 68.0±10.3# | n.s. |
| basophils | 1.7±4.0×104 | 7.0±3.0×103 | n.s. | 0.2±0.5# | 0.1±0.3# | n.s. |
| eosinophils | 1.4±1.4×105 | 1.3±1.0×105 | n.s. | 2.5±2.6# | 0.9±0.7# | p<0.05 |
| monocytes | 5.0±1.5×105 | 8.5±2.6×105 | p<0.001 | 7.5±2.3# | 6.5±1.7# | n.s. |
| lymphocytes | 2.0±0.7×106 | 3.0±1.3×106 | p<0.01 | 28.7±8.5# | 24.0±9.6# | n.s. |
| CD3+ cells | 1.5±0.6×106 | 2.3±1.0×106 | p<0.001 | 58.0±11.0§ | 58.0±9.0§ | n.s. |
| CD8+ cells | 4.0±2.5×105 | 5.8±3.1×105 | p<0.001 | 24.5±9.0$ | 24.3±7.5$ | n.s. |
| CD4+ cells | 11.0±4.0×105 | 18.0±7.7×105 | p<0.001 | 75.5±9.0$ | 75.7±7.5$ | n.s. |
| FOXP3+ cells* | 6.2±3.5×104 | 8.2±4.7×104 | p<0.05 | 4.0±1.5‡ | 3.4±1.5‡ | p<0.05 |
| AITR+ cells* | 8.9±6.8×103 | 10.0±9.0×103 | n.s. | 0.6±0.4‡ | 0.5±0.3‡ | n.s. |
| CD127low cells* | 5.6±2.4×104 | 10.0±6.0×104 | p<0.001 | 4.0±1.3‡ | 5.0±3.0‡ | p<0.05 |
| CTLA4+ cells* | 1.6±0.7×105 | 3.0±2.0×105 | p<0.05 | 13.8±11.5‡ | 15.6±12.5‡ | n.s. |
* = as subpopulation of CD4+CD25high cells.
# = % out of leukocyte cells ± SD.
§ = % out of PBMC ± SD.
$ = % out of CD3+ cells ± SD.
‡ = % out of CD4+ cells ± SD.